Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients
Frontiers in Oncology · 15.07.2026 · 16
DOI: 10.3389/fonc.2026.1876224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 15.07.2026. Verfasst von Caterina Gianni und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Oncology and Hematology, Medical Oncology and Breast Unit, Istituto di Ricovero e Cura a Carattere Scientific…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The immune system is known to be involved in the microenvironment of triple negative breast cancer (TNBC). Immune ratios such as the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the monocyte-to-lymphocyte ratio (MLR), and the systemic immune-inflammation index (SII) may reflect the functional status of the immune system in these patients and the involvement of circulating immune cells in cancer progression.
Methods
We conducted a retrospective-prospective, observational multicenter analysis to investigate the association between inflammatory indexes (NLR, PLR, MLR, and SII), clinical characteristics and survival outcomes in patients with metastatic TNBC in the first-line setting.
Results
Data from 114 consecutive patients with a diagnosis of metastatic TNBC were evaluated. At a median follow-up of 28 months, median PFS in the overall patient population was 8.6 months (95% CI 6.5–9.6), while median OS was 17.7 months (95% CI 13.7–23.9). All high inflammation-based scores evaluated at the diagnosis of metastatic disease were significantly associated with lower PFS, particularly high NLR (≥3), high MLR (≥0.34), high PLR (≥210), and high SII (≥836) (p <0.0001, p <0.0001, p = 0.0002, p <0.0001, respectively). Similarly, all indexes appeared to be significantly associated with lower OS, particularly NLR (≥3), SII (≥836), PLR (≥210), and MLR (≥0.34) (p <0.0001, p = 0.001, p = 0.002, and p = 0.0006, respectively). In multivariable analysis for predictors of OS, the number of metastatic sites, NLR, SII, and MLR remained significant.
Conclusions
NLR, PLR, SII, and MLR are associated with PFS and OS in metastatic TNBC. Although our results require validation in larger prospective studies and contemporary cohorts treated with chemoimmunotherapy and novel agents, inflammatory ratios may represent feasible prognostic biomarkers in metastatic TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Oncology and Hematology, Medical Oncology and Breast Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Ama…
- Unit of Biostatistics and Clinical Trials, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori,", Meldola, Italy.
- U.O. Epidemiologia Clinica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera Metropolitana, Genova, Italy.
- Pharmaceutical Department, Unità Sanitaria Locale (USL) Toscana Centro, Prato, Italy.
- Department of Medicine (DMED), University of Udine, Udine, Italy.
- Department of Medical Oncology, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Zitieren
APA
Gianni, C., Scarpi, E., Blondeaux, E., Palleschi, M., Merloni, F., Gasperoni, L., Puglisi, F., Collovà, E., Pugliese, P., Cognetti, F., Giannubilo, I., Ruelle, T., Del Mastro, L., Bighin, C., Musolino, A., & De Giorgi, U. (2026). Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1876224
Vancouver
Gianni C, Scarpi E, Blondeaux E, Palleschi M, Merloni F, Gasperoni L, et al. Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1876224
BibTeX
@article{Gianni2026,
author = {Gianni, Caterina and Scarpi, Emanuela and Blondeaux, Eva and Palleschi, Michela and Merloni, Filippo and Gasperoni, Lorenzo and Puglisi, Fabio and Collovà, Elena and Pugliese, Palma and Cognetti, Francesco and Giannubilo, Irene and Ruelle, Tommaso and Del Mastro, Lucia and Bighin, Claudia and Musolino, Antonino and De Giorgi, Ugo},
title = {Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1876224}
}
EUVIMED